HIPGEN: a randomized, multicentre phase III study using intramuscular PLacenta-eXpanded stromal cells therapy for recovery following hip fracture arthroplasty <subtitle>a study design</subtitle>

HIPGEN: a randomized, multicentre phase III study using intramuscular PLacenta-eXpanded stromal cells therapy for recovery following hip fracture arthroplasty <subtitle>a study design</subtitle>

Aims The aim of the HIPGEN consortium is to develop the first cell therapy product for hip fracture patients using PLacental-eXpanded (PLX-PAD) stromal cells. Methods HIPGEN is a multicentre, multinational, randomized, double-blind, placebo-controlled trial. A total of 240 patients aged 60 to 90 yea...

Full description

Bibliographic Details
Main Authors: Tobias Winkler, Matthew L. Costa, Racheli Ofir, Ornella Parolini, Sven Geissler, Hans-Dieter Volk, Christian Eder
Format: Article
Language:English
Published: The British Editorial Society of Bone & Joint Surgery 2022-04-01
Series:Bone & Joint Open
Subjects:
Hip fracture
Femoral neck fracture
Allogeneic cell therapy
Cell therapy
PLX-PAD
stromal cells
Online Access:https://online.boneandjoint.org.uk/doi/10.1302/2633-1462.34.BJO-2021-0156.R1

Internet

https://online.boneandjoint.org.uk/doi/10.1302/2633-1462.34.BJO-2021-0156.R1

Similar Items